David Butler, PhD, is the Chief Technology Officer at Hongene Biotech Corporation, a fully integrated raw materials supplier and CDMO services provider that is focused on the RNA manufacturing space, the scope of which includes mRNA therapeutics, vaccines, siRNA, antisense oligonucleotides, diagnostics, and gene editing. Prior to Hongene, he led organizations driving drug discovery and development of oligonucleotide therapeutics as VP and Head of Medicinal Chemistry at Wave Life Sciences, VP and Head of Therapeutics Development at Alltrna, and VP and Head of Chemistry at Korro Bio. He also spent time as a Principal Scientist at Alnylam Pharmaceuticals developing early LNP technologies for siRNA delivery that were the progenitors of those used for mRNA related products today. He is passionate about team building, working with individuals and companies to help them succeed, and leveraging novel technologies to advance RNA medicines more efficiently and safely.